This peer-reviewed analysis critically examines BPC-157’s development barriers as a pharmaceutical candidate, identifying significant unresolved challenges: no approved formulation exists, dosing regimens lack validation, and no Phase II trials have been completed despite 30+ years of preclinical research. The paper systematically addresses biopharmaceutical obstacles including physicochemical properties, pharmacokinetic-pharmacodynamic disconnects, formulation hurdles across administration routes, and regulatory/translational barriers. For practitioners and supplement brands, this represents authoritative documentation of why BPC-157 remains investigational and the specific scientific gaps between preclinical promise and clinical reality.
For your business
BPC-157 lacks validated dosing, approved formulation, and Phase II trial data — inform patients this remains investigational with significant translational gaps.